Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2025

Primary Completion Date

October 24, 2033

Study Completion Date

October 24, 2033

Conditions

Hemophilia B

Interventions

GENETIC

CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)

Administered as a single IV infusion.

Trial Locations (2)

RECRUITING

University of Florida - 84000399, Gainesville

RECRUITING

University of Michigan Medical Center - 84000491, Ann Arbor